DBV Technologies (DBVT) Assets Average (2015 - 2026)
DBV Technologies (DBVT) reported Assets Average of $250.0 million for Q1 2026, up 330.3% year-over-year from $58.1 million in Q1 2025, and up 45.3% on a QoQ basis from $172.1 million in Q4 2025.
DBV Technologies (DBVT) has 11 years of Assets Average data on file, last reported at $250.0 million in Q1 2026.
- Quarterly Assets Average rose 330.3% year-over-year to $250.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $250.0 million (up 330.3% YoY) and the FY2025 annual result came in at $149.7 million, up 20.4% from the prior year.
- Assets Average climbed to $250.0 million in Q1 2026 per DBVT's latest filing, from $172.1 million in the prior quarter.
- Across five years, Assets Average topped out at $266.5 million in Q3 2022 and bottomed at $58.1 million in Q1 2025.
- The 5-year median for Assets Average is $172.1 million (2025), against an average of $169.6 million.
- The widest annual swing landed in 2025, when Assets Average plunged 64.66%; it then surged 330.3% in 2026.
- Tracing DBVT's Assets Average over 5 years: stood at $247.3 million in 2022, then fell by 24.64% to $186.4 million in 2023, then sank by 57.42% to $79.4 million in 2024, then surged by 116.87% to $172.1 million in 2025, then surged by 45.3% to $250.0 million in 2026.
- Per Business Quant, the three latest DBVT Assets Average figures stand at $250.0 million (Q1 2026), $172.1 million (Q4 2025), and $127.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 250.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 250.05 Mn |
| Dec 31, 2025 | 172.10 Mn |
| Sep 30, 2025 | 126.96 Mn |
| Jun 30, 2025 | 97.00 Mn |
| Mar 31, 2025 | 58.11 Mn |
| Dec 31, 2024 | 79.36 Mn |
| Sep 30, 2024 | 103.62 Mn |
| Jun 30, 2024 | 130.04 Mn |
| Mar 31, 2024 | 164.44 Mn |
| Dec 31, 2023 | 186.38 Mn |
| Sep 30, 2023 | 203.65 Mn |
| Jun 30, 2023 | 225.22 Mn |
| Mar 31, 2023 | 239.72 Mn |
| Dec 31, 2022 | 247.32 Mn |
| Sep 30, 2022 | 266.55 Mn |
| Jun 30, 2022 | 201.28 Mn |
| Mar 31, 2022 | 132.15 Mn |
| Dec 31, 2021 | 158.82 Mn |
| Sep 30, 2021 | 185.75 Mn |
| Jun 30, 2021 | 210.99 Mn |
| Mar 31, 2021 | 246.83 Mn |
| Dec 31, 2019 | 219.48 Mn |
| Sep 30, 2019 | 190.71 Mn |
| Jun 30, 2019 | 202.89 Mn |
| Jun 30, 2018 | 254.02 Mn |
| Dec 31, 2017 | 235.47 Mn |
| Jun 30, 2017 | 286.01 Mn |
| Dec 31, 2016 | 340.54 Mn |
| Jun 30, 2016 | 373.47 Mn |
| Dec 31, 2015 | 253.90 Mn |
| Jun 30, 2015 | 144.13 Mn |